> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 16 Observations on Lupin Unit FDA-483
- URL: https://www.fdaweb.com/16-observations-on-lupin-unit-fda-483/
- Published: 2022-12-08T12:00:00.000Z
- Updated: 2026-09-14T18:09:04.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5153353

FDA has released the form FDA-483 issued following an 11/13-11/21 inspection at the Lupin Unit 1 drug manufacturing facility in Pradesh, India. The form contains these 16 inspection observations:

- failing to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications, whether or not the batch has been already distributed;
- failing to exercise appropriate controls over computer or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel;
- failing to establish written procedures for evaluations conducted at least annually to review records associated with a representative number of batches, whether approved or rejected;
- failing to maintain for at least one year after the expiration date all records of production, control, distribution, components, and labeling associated with a batch of drug products;
- equipment used in the manufacture, processing, packing, or holding of a drug product lack appropriate design to facilitate operations for its intended use for its cleaning and maintenance;
- failing to perform routine calibration of automatic and mechanical equipment according to a written program designed to assure proper performance;
- failing to place in writing and fully follow the responsibilities and procedures applicable to the quality control unit;
- redacted dosage forms are manufactured within a Grade D (ISO 8) manufacturing area/environment;
- investigations are inadequate to determine the root cause for the failure of a batch of intermediate or active pharmaceutical ingredient (API) to meet specifications, whether or not the batch has been already distributed;
- critical process parameters identified in the manufacture of APIs and API intermediates are not appropriately (continually) monitored;
- computer systems do not have sufficient controls to prevent unauthorized access or changes to data;
- issues involving a redacted marketing complaint;
- issues involving redacted validation batch production records;
- concerns about a Good Engineering Practices training module;
- a standard procedure for the preparation, approval, issue, and control of a Drawing Layout is silent on the content of the review and approval process; and
- a redacted API is manufactured within a Grade D (ISO 8) manufacturing area/environment.